---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-005968"
form_type: "8-K"
ticker: "CRVS"
cik: "0001626971"
company_name: "Corvus Pharmaceuticals, Inc."
filed_at: "2026-01-23T23:59:59+00:00"
generated_at: "2026-05-16T08:25:38.977331+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Corvus Pharmaceuticals prices $22.15/share public offering of ~9.1M shares for ~$188.3M net proceeds

## Summary
- Upsized public offering of 7,900,677 shares at $22.15/share; underwriters fully exercised 30-day option for 1,185,101 additional shares.
- Expected net proceeds of approximately $188.3 million after underwriting discounts and expenses.
- Net proceeds to fund working capital and R&D for Phase 3 T cell lymphoma and Phase 2 atopic dermatitis, hidradenitis suppurativa, and asthma trials.
- Offering expected to close on January 23, 2026; Jefferies and Goldman Sachs acted as lead underwriters.

## SEC filing metadata
- accession: 0001104659-26-005968
- form_type: 8-K
- ticker: CRVS
- cik: 0001626971
- company_name: Corvus Pharmaceuticals, Inc.
- filed_at: 2026-01-23T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1626971/000110465926005968/0001104659-26-005968-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1626971/000110465926005968/tm263501d7_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-005968
- JSON: https://secwatch.observer/filing/0001104659-26-005968.json
- Plain text: https://secwatch.observer/filing/0001104659-26-005968.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.